Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Kyu-Yu-Kai, Efco to Merge in April
February 11, 2002
- Survey Shows Marked Decreases in People's Interest in Science
February 11, 2002
- P&G to Sell Vicks Medicated Drop Business
February 11, 2002
- REGULATORY NEWS IN BRIEF
February 11, 2002
- Olympus Develops DNA Computer for Gene Analysis
February 11, 2002
- Yamanouchi, Sumitomo Chemical Tie Up on Knockout Mice with Transgenic Inc
February 11, 2002
- Eiken Develops New Bovine Embryo Sexing Reagent
February 11, 2002
- Tanabe Ties Up with Menarini to Develop Antitumor Agent
February 11, 2002
- BML to Merge 2 Subsidiaries
February 11, 2002
- Mochida to Expand Its Business Fields
February 11, 2002
- LDP to Review Safety Measures against Medical Devices
February 11, 2002
- Sankyo to Beef Up Business Development in China
February 11, 2002
- Shimadzu: Multi-channel Oxygen Monitors
February 11, 2002
- WEBSITE NEWS
February 11, 2002
- Brand Generic Business Likely to Be Brisk
February 11, 2002
- BUSINESS NEWS IN BRIEF
February 11, 2002
- Wholesalers Concerned over Effects of Medical Fee Cut: JPPA
February 11, 2002
- Korosho's Preparations for NHI Price Revision Delay
February 4, 2002
- WEBSITE NEWS
February 4, 2002
- Ordinary Session of Diet to Deal with Budgets
February 4, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…